Citation Impact
Citing Papers
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
2009 Standout
Global trends in esophageal cancer mortality with predictions to 2025, and in incidence by histotype
2023
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
2018
Instant Intracellular Delivery of miRNA via Photothermal Effect Induced on Plasmonic Pyramid Arrays
2021
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Novel therapeutics for coronary artery disease from genome-wide association study data
2015
Cell type-selective secretome profiling in vivo
2020 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
2012 Standout
American College of Gastroenterology Guideline: Management of Acute Pancreatitis
2013 Standout
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
2012
Cell Biology of Ischemia/Reperfusion Injury
2012 Standout
Pharmacotherapy for NASH: Current and emerging
2017
New and experimental therapies for HCV
2009
Acute Pancreatitis
2016 Standout
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
2016 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
2018
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
2016 Standout
Non-alcoholic fatty liver disease
2021 Standout
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661
2011
Therapeutic Landscape for NAFLD in 2020
2020
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Host – hepatitis C viral interactions: The role of genetics
2016
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
2010
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
2019
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease
2020
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
2019
Adverse events associated with ERCP
2016 Standout
Platelet responses to intravenous infusion of Intralipid in healthy volunteers
1990
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment
2023
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away
2007
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
2019
Bleeding Disorder from the “Fat Overload” Syndrome
1984
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
2019
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
ESPGHAN and ESPEN Guidelines Paediatric Parenteral Nutrition ‐ Annex: List of Products
2005 Standout
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data
2020
Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design
2013 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of S. Harrison being referenced
Blood platelet behaviour during infusion of an Intralipid based intravenous feeding mixture
1982
Characteristics and Outcomes of Patients Undergoing Debridement of Pancreatic Necrosis
2009
What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer?
2017
Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report
2021
Improving outcomes in patients with oesophageal cancer
2023
The genetics of coronary heart disease
2012
Molecular Analysis of Inflammatory Markers in Trauma Patients at Risk of Postinjury Complications
2007
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study
2018
308 VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN
2010
Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis
2017
Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis
2017
A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH
2017
126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY
2009
BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study
2017
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
2018
A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
2018
Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
2017
993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN
2008